Drug intelligence / Profile preview

bortezomib + carboplatin + paclitaxel

Development stage: Unknown
Lead developer: Millennium Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A three-drug combination regimen consisting of bortezomib (a proteasome inhibitor), carboplatin (a platinum-based chemotherapy agent), and paclitaxel (a taxoid chemotherapeutic agent). This combination has been studied in clinical trials for various cancer types including metastatic esophageal cancer and non-small cell lung cancer. The regimen works through multiple mechanisms: bortezomib inhibits the 26S proteasome leading to cell cycle arrest and apoptosis, while paclitaxel acts as a mitotic inhibitor and carboplatin forms DNA adducts that disrupt cellular function.

Targets

DNAPSMB5 (Proteasome subunit beta Type-5)TUBB (Tubulin (alpha and beta subunits))PSMB9 (Immunoproteasome subunit beta type-1i)

Beyond the preview

Go deeper on bortezomib + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bortezomib + carboplatin + paclitaxel.

Explore the full profile